Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and histologic examinations of completely resected specimens. A 54-year-old man with hepatitis C virus (HCV)-related liver cirrhosis (LC) presented to our unit. A CT scan demonstrated a 3.8-cm arterial hypervascular/portal-washout mass in the right lobe and invasion in the right portal vein. Twelve weeks after beginning sorafenib therapy, the AFP level was normalized and a CT scan showed a prominent decrease in the hepatic mass and a significant decrease in the volume of portal vein thrombosis (PVT). The patient received a right liver hemihepatectomy after 12 months. No viable tumor cells were found in the resected specimen, and there was no thrombotic obstruction of the portal vein. Twelve months later the patient showed no clinical evidence of HCC recurrence. This is the first case of CR in HCC treatment following sorafenib with histologically confirmed HCV-related HCC without LC evidence, HCC with PVT, and a follow-up of longer than 12 months. This case seems to be an extremely unusual clinical outcome in advanced HCC.
Abstract
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and histologic examinations of completely resected specimens. A 54-year-old man with hepatitis C virus (HCV)-related liver cirrhosis (LC) presented to our unit. A CT scan demonstrated a 3.8-cm arterial hypervascular/portal-washout mass in the right lobe and invasion in the right portal vein. Twelve weeks after beginning sorafenib therapy, the AFP level was normalized and a CT scan showed a prominent decrease in the hepatic mass and a significant decrease in the volume of portal vein thrombosis (PVT). The patient received a right liver hemihepatectomy after 12 months. No viable tumor cells were found in the resected specimen, and there was no thrombotic obstruction of the portal vein. Twelve months later the patient showed no clinical evidence of HCC recurrence. This is the first case of CR in HCC treatment following sorafenib with histologically confirmed HCV-related HCC without LC evidence, HCC with PVT, and a follow-up of longer than 12 months. This case seems to be an extremely unusual clinical outcome in advanced HCC.
참고문헌 (20)
- "A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators", Hepatology, 28, pp.751~755 (1998)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Lencioni R, "Modified RECIST (mRECIST) assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Yeo W, "A randomized phase III study of doxorubicin versus cisplatin", interferon alpha-2b, fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma, pp.J Natl Cancer Inst, 2005[DOI]
- Zhu AX., "Systemic therapy of advanced hepatocellular carcinoma:how hopeful should we be?", Oncologist, 11, pp.790~800 (2006)
- Wilhelm SM, "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling", Mol Cancer Ther, 7, pp.3129~3140 (2008)
- Inuzuka T, "Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report", Oncology, 81, pp.152~157 (2011)
- So BJ, "Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report", J Hematol Oncol, 1, pp.18~ (2008)
- Yeganeh M, "Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib", Am J Transplant, 9, pp.2851~2854 (2009)
- Wang SX, "Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report", Target Oncol, 5, pp.59~63 (2010)
- Kudo M, "Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan", Oncology, 78, pp.154~166 (2010)
- Chelis L, "Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART? A case report", Med Oncol, 28(Suppl 1), pp.S165~S168 (2011)
- Sacco R, "Complete response for advanced liver cancer during sorafenib therapy: case report", BMC gastroenterol, 11, pp.4~ (2011)
- Curtit E, "Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report", J Clin Oncol, 29, pp.e330~e332 (2011)
- Irtan S, "Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection", Liver Int, 31, pp.740~743 (2011)
- Mizukami H, "Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma", Case Rep Oncol, 5, pp.380~384 (2012)
- Kim MS, "Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report", World J Gastrointest Oncol, 5, pp.38~42 (2013)
- Kermiche-Rahali S, "Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib", World J Surg Oncol, 11, pp.171~ (2013)
- Moroni M, "Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma", Future Oncol, 9, pp.1231~1237 (2013)